Tauro ursodeoxycholic acid (TUDCA) inhibits human fibrosarcoma HT-1080 cell invasion through MMPs inactivation and the modulation of the MAPKs signaling pathway

Key Points

• TUDCA significantly reduces fibrosarcoma HT-1080 cell invasion through MMPs inhibition.
• Inhibition of MMP activity was observed, leading to decreased invasion rates by more than 50%.
• Analysis of MAPK signaling pathway showed modulation in response to TUDCA treatment, revealing functional changes.
• Future studies should explore TUDCA's potential as a therapeutic agent against fibrosarcoma, with broader clinical implications.